Clinical trial

Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC

NCT07093762

Drugs and interventions used in this trial

1 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

Search this trial's interventions

DRUG · Unmapped registry intervention Atezolizumab+Bevacizumab+Carboplatin+Paclitaxel Find medicine records · Find other trials using this name

Study at a glance

Registry-backed

Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC

Design: OBSERVATIONAL · Status: NOT YET RECRUITING · Phase: Not specified

Read study objectives, eligibility and outcome measures at ClinicalTrials.gov

StatusNOT_YET_RECRUITING

Study typeOBSERVATIONAL

Start date2025-08-20

PhaseN/A

Conditions

Non Small Cell Lung Cancerunresolved

Interventions

Atezolizumab+Bevacizumab+Carboplatin+PaclitaxelDRUG

Sponsors & collaborators

Fuzhou General Hospitallead sponsor

900th Hospital of PLA Joint Logistic Support Forcecollaborator

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT07093762 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.